All stock lists
Unlock the score
Pulse Biosciences, Inc. (NASDAQ:PLSE)
US · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
52.66-0.36 (-0.68%)
Market cap
$3.76B
Insider Score
Health Score
Analyst consensus
Listed since
May 18, 2016
Website
Insider Score
/ 100
PLSE Insider Score
PULSE BIOSCIENCES, INC. has a live Insider Score.
Scored on 4 qualifying trades from 1 insider in the last 90 days.
Financial Health Score
Fair
From PLSE’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $1.2M
- Net income
- -$80.1M
- Net margin
- -6755.8%
Leverage19 / 20
Little or no net debt.
- Total debt
- $6.8M
- Cash
- $101.6M
- Debt / equity
- 0.07
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $105.7M
- Current liabilities
- $11.0M
- Current ratio
- 9.63
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$61.1M
- Free cash flow
- -$61.4M
- FCF margin
- -5180.4%
Dilution & runway16 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 69.2M
- Share growth (1y)
- 2.9%
- Cash runway
- 20 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
PLSE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 434.00 K | 401.00 K | 264.00 K | 86.00 K | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 273.00 K | 370.00 K | 519.00 K | 279.00 K | 267.00 K | 0.00 |
| Gross Profit | 161.00 K | 31.00 K | -255.00 K | -193.00 K | -267.00 K | 0.00 |
| SG&A Expense | 8.46 M | 6.59 M | 7.07 M | 8.78 M | 8.19 M | 7.73 M |
| R&D Expense | 16.98 M | 12.59 M | 10.93 M | 11.39 M | 12.09 M | 10.31 M |
| Operating Expenses | 25.43 M | 19.18 M | 18.00 M | 20.17 M | 20.01 M | 18.04 M |
| Operating Income | -25.27 M | -19.15 M | -18.25 M | -20.37 M | -20.27 M | -18.04 M |
| Pretax Income | -24.66 M | -18.58 M | -17.43 M | -19.39 M | -19.17 M | -16.80 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -24.66 M | -18.58 M | -17.43 M | -19.39 M | -19.17 M | -16.80 M |
| EPS (Basic) | -0.36 | -0.26 | -0.26 | -0.29 | -0.28 | -0.25 |
| EPS (Diluted) | -0.36 | -0.26 | -0.26 | -0.29 | -0.28 | -0.25 |
| Shares Outstanding | 69.20 M | 67.79 M | 67.40 M | 67.39 M | 67.28 M | 67.13 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.